Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Susan Benedict Navia"'
Autor:
Daniel Carvajal-Hausdorf, Ana Luisa Soares Neves, Diego Greatti Vaz da Silva, Alberto Durán-Peña, Eladio Radhames Perez Antonio, Pedro Oliveira, Camelia Tang Qian Ying, Danielli Matsuura, Gustavo Costa Nascimento de Carvalho, Tatiana Nayara Libório-Kimura, Mariane Schäffer Castro, Sachin Thigale, Matteo Guidetti, Vahid Nouri Kandany, Bruno Soares Rocha Calabria, Marianne Zelniker, Susan Benedict Navia, Ahmed Abdallah Ahmed Abdallah, Cassiano Ricardo de Oliveira Berto, Elly Pichardo, Edson Santos Ferreira Filho, Ana Isabel Sanchez-Barbero, Arturo Tamayo, Kamran Mushtaq, Denise Saretta Schwartz, Lucas Augusto Pepe Mena, Maria del Pilar Estrella Caballero, Carlos Augusto Rossetti, Khalid Al-Karbi, Ahmed Doomi, Eduardo Dytz Almeida, Gustavo de Almeida, Clarissa Medeiros
Publikováno v:
Principles and Practice of Clinical Research Journal. 6:25-32
Introduction: Primary dysmenorrhea affects many women, being a major cause of absenteeism and reduced productivity at work and at school. Although non-steroidal anti-inflammatory drugs (NSAIDs) are a good treatment option, up to 18% of women show no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ab2e43ec22ecad87baa7b85afac9b6a
https://doi.org/10.21801/ppcrj.2020.62.5
https://doi.org/10.21801/ppcrj.2020.62.5
Autor:
Michael Robert Migden, Jason J. Luke, Wanxing Chai-Ho, Meenal Kheterpal, Trisha Michel Wise-Draper, Andrew Stewart Poklepovic, Diana Bolotin, Claire F. Verschraegen, Frances A. Collichio, Jennifer Tang, Gregory A. Daniels, Katy K. Tsai, Susan Benedict Navia, Haifeng Zhang, Christoph Matthias Ahlers
Publikováno v:
Journal of Clinical Oncology. 40:TPS9597-TPS9597
TPS9597 Background: RP1 is an oncolytic virus (HSV-1) that expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM-CSF). In preclinical studies, RP1 induced immunogenic tumor cell death and provided po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d40870b9e4c93ee70b40753db5cbaa0a
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9597
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9597
Autor:
Aristeidis Chaidos, Jennifer Whalen, John Radford, Susan Benedict Navia, Gilles Salles, Pamela McKay, Damaj Gandhi Laurent, Anand Rajarethinam, Hervé Tilly, Vincent Ribrag, Stephen Opat, Tycel Phillips, Franck Morschhauser, Philip Campbell, Wojciech Jurczak, Deyaa Adib
Publikováno v:
Blood. 134:123-123
Introduction: Relapsed/refractory (R/R) follicular lymphoma (FL) remains a difficult-to-treat condition, with limited treatment options. New, tolerable treatments with unique mechanisms of action are needed, especially for high-risk patients whose di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad52559582f068a6d0d71133282f6672
https://doi.org/10.1182/blood-2019-128096
https://doi.org/10.1182/blood-2019-128096